Abstract Glypican-3 (GPC3) is a cell surface oncofetal proteoglycan that is anchored by
glycosylphosphatidylinositol. Whereas GPC3 is abundant in fetal liver, its expression is …

Hepatocellular carcinoma (HCC) is a malignant tumor with a fairly poor prognosis (5-year
survival of less than 50%). Using sorafenib, the only food and drug administration (FDA) …

Background: Glypican-3 (GPC3) has been widely recognized in the progression of liver
tumors for several years. The relationship between overexpression of GPC3 and the poorer …

Hepatocellular carcinoma (HCC) is one of the most deadly cancers worldwide. In patients
with HCC, histopathogical differentiation is an important indicator of prognosis; however …

Abstract Backgrounds Glypican-3 (GPC3) has been implicated in tumor development and
progression for several years. However, the prognostic significance of GPC3 expression in …

Glypican-3 (GPC3) is a developmentally-regulated oncofetal protein that has been
established as a clinically-relevant biomarker for early hepatocellular carcinoma (HCC). It is …

Background: GC33 is a recently developed monoclonal antibody against human glypican‐3
(GPC3), which is significantly upregulated in hepatocellular carcinoma (HCC). GC33 …

Glypican-3 (GPC3), a member of heparan sulfate proteoglycans, attaches to the cell
membrane and is frequently observed to be elevated in hepatocellular carcinoma (HCC) …

Glypican-3 (GPC3) is an oncofetal glycoprotein attached to the cell membrane by a
glycophosphatidylinositol anchor. GPC3 is overexpressed in some kinds of tumors …

Glypican-3 (GPC3), a 65 kD protein consisting of 580 amino acids, is a heparan sulfate
proteoglycan bound to the cell membrane by glycosylphosphatidylinositol. This protein is …